Human Molecular Genetics Advance Access originally published online on May 19, 2006
Human Molecular Genetics 2006 15(13):2059-2075; doi:10.1093/hmg/ddl131
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin–protein ligase with monoubiquitylation capacity
1 Neurologie et Thérapeutique Expérimentale, INSERM U679-Université Pierre & Marie Curie, Paris VI, Hôpital de la Pitié-Salpêtrière, 75013 Paris, France, 2 Département de Génétique, Cytogénétique et Embryologie, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France and 3 Fédération de Neurologie, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France
* To whom correspondence should be addressed. Tel: +33 142162217; fax: +33 144243658; Email: corti{at}ccr.jussieu.fr
Received January 26, 2006; Revised April 4, 2006; Accepted May 12, 2006
Mutations in the parkin gene, encoding an E3 ubiquitin–protein ligase, are a frequent cause of autosomal recessive parkinsonism and are also involved in sporadic Parkinson's disease. Loss of Parkin function is thought to compromise the polyubiquitylation and proteasomal degradation of specific substrates, leading to their deleterious accumulation. Several studies have analyzed the effects of parkin gene mutations on the biochemical properties of the protein. However, the absence of a cell-free system for studying intrinsic Parkin activity has limited the interpretation of these studies. Here we describe the biochemical characterization of Parkin and 10 pathogenic variants carrying amino-acid substitutions throughout the sequence. Mutations in the RING fingers or the ubiquitin-like domain decreased the solubility of the protein in detergent and increased its tendency to form visible aggregates. None of the mutations studied compromised the binding of Parkin to a series of known protein partners/substrates. Moreover, only two variants with substitutions of conserved cysteine residues of the second RING finger were inactive in a purely in vitro ubiquitylation assay, demonstrating that loss of ligase activity is a minor pathogenic mechanism. Interestingly, in this in vitro assay, Parkin catalyzed the linkage of single ubiquitin molecules only, whereas the ubiquitin–protein ligases CHIP and Mdm2 promoted the formation of polyubiquitin chains. Similarly, in mammalian cells Parkin promoted the multimonoubiquitylation of its substrate p38, rather than its polyubiquitylation. Thus, Parkin may mediate polyubiquitylation or proteasome-independent monoubiquitylation depending on the protein context. The discovery of monoubiquitylated Parkin species in cells hints at a novel post-translational modification potentially involved in the regulation of Parkin function.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. A. Hristova, S. A. Beasley, R. J. Rylett, and G. S. Shaw Identification of a Novel Zn2+-binding Domain in the Autosomal Recessive Juvenile Parkinson-related E3 Ligase Parkin J. Biol. Chem., May 29, 2009; 284(22): 14978 - 14986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ehrlund, E. H. Anthonisen, N. Gustafsson, N. Venteclef, K. Robertson Remen, A. E. Damdimopoulos, A. Galeeva, M. Pelto-Huikko, E. Lalli, K. R. Steffensen, et al. E3 Ubiquitin Ligase RNF31 Cooperates with DAX-1 in Transcriptional Repression of Steroidogenesis Mol. Cell. Biol., April 15, 2009; 29(8): 2230 - 2242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Rubio de la Torre, B. Luzon-Toro, I. Forte-Lago, A. Minguez-Castellanos, I. Ferrer, and S. Hilfiker Combined kinase inhibition modulates parkin inactivation Hum. Mol. Genet., March 1, 2009; 18(5): 809 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Klein and K. Lohmann Parkinson disease(s): Is "Parkin disease" a distinct clinical entity? Neurology, January 13, 2009; 72(2): 106 - 107. [Full Text] [PDF]
|
|
|
|
|
|
J. S. Schlehe, A. K. Lutz, A. Pilsl, K. Lammermann, K. Grgur, I. H. Henn, J. Tatzelt, and K. F. Winklhofer Aberrant Folding of Pathogenic Parkin Mutants: AGGREGATION VERSUS DEGRADATION J. Biol. Chem., May 16, 2008; 283(20): 13771 - 13779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kawahara, M. Hashimoto, P. Bar-On, G. J. Ho, L. Crews, H. Mizuno, E. Rockenstein, S. Z. Imam, and E. Masliah {alpha}-Synuclein Aggregates Interfere with Parkin Solubility and Distribution: ROLE IN THE PATHOGENESIS OF PARKINSON DISEASE J. Biol. Chem., March 14, 2008; 283(11): 6979 - 6987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Klein and M. G. Schlossmacher Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder Neurology, November 27, 2007; 69(22): 2093 - 2104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Cookson, W. Dauer, T. Dawson, E. A. Fon, M. Guo, and J. Shen The Roles of Kinases in Familial Parkinson's Disease J. Neurosci., October 31, 2007; 27(44): 11865 - 11868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Olzmann, L. Li, M. V. Chudaev, J. Chen, F. A. Perez, R. D. Palmiter, and L.-S. Chin Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6 J. Cell Biol., September 7, 2007; 178(6): 1025 - 1038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Joch, A. R. Ase, C. X.-Q. Chen, P. A. MacDonald, M. Kontogiannea, A. T. Corera, A. Brice, P. Seguela, and E. A. Fon Parkin-mediated Monoubiquitination of the PDZ Protein PICK1 Regulates the Activity of Acid-sensing Ion Channels Mol. Biol. Cell, August 1, 2007; 18(8): 3105 - 3118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zhou, S. V. Patel, and P. M. Snyder Nedd4-2 Catalyzes Ubiquitination and Degradation of Cell Surface ENaC J. Biol. Chem., July 13, 2007; 282(28): 20207 - 20212. [Abstract] [Full Text] [PDF]
|
|